Phase I-II

112 Results

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Clinical Trials 2.0: A Fresh Approach to Systems and Data

CMED | 01-Mar-2021 | Technical / White Paper

This white paper explores the value of taking a fresh approach to clinical data management, its associated systems and ultimately the processes and roles...

Deploy Configurable, Mixed-Modality ePRO Solutions, Fast

Clinical Ink | 01-Mar-2021 | Data Sheet

Real-Time, Integrated Data Capture With Unprecedented Freedom of Choice

A Winning End-to-End Solution for Oncology Studies

Clinical Ink | 22-Feb-2021 | Technical / White Paper

Oncology clinical trials present a unique set of challenges for patients, study sites, and study sponsors. Using electronic patient reported outcomes (ePRO)...

Exploring the Intricacies of the Immune System: A Practical Guide to Immune Monitoring Across Therapeutic Interventions

Precision for Medicine | 01-Feb-2021 | Insight Guide

Immune monitoring has become an essential strategy for understanding, predicting, and monitoring the response of the immune system to therapeutic interventions....

Why automating clinical trials is essential

Formedix | 18-Jan-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Global Pediatric Drug Development Collaboration: Part Two

PRA Health Sciences | 09-Jul-2020 | Technical / White Paper

70% of medicines given to children have never been studied in pediatric populations. Children who need treatments represent a relatively small population....

Global Pediatric Drug Development Collaboration: Part One

PRA Health Sciences | 09-Jul-2020 | Technical / White Paper

The pharmaceutical industry is unlike any other industry in that the products manufactured can dramatically improve, and even save, lives. This is especially...